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Molecular proﬁling of endometrial neoplasms reveals genetic changes in endometrial carcinomas that support the dualistic model,
in which type I carcinomas are estrogen-dependent, low grade lesions and type II carcinomas are nonestrogen dependent and high
grade. The molecular changes in type I endometrial carcinomas include mutations in PTEN, PIK3CA, KRAS, and β-catenin, along
with microsatellite instability, whereas type II endometrial carcinomas are characterized by genetic alterations in p53, HER2/neu,
p16, and E-cadherin. For endometrial neoplasms with a malignant mesenchymal component, C-MYC mutations and loss of
heterozygosity are frequently seen in carcinosarcomas, and a fusion gene, JAZF1/JJAZ1, is distinctive for endometrial stromal
sarcoma. In addition, p53 mutations may play an important role in tumorigenesis of undiﬀerentiated endometrial sarcoma. These
molecular changes can help in the diagnosis of endometrial neoplasms, as well as form the basis of molecular targeted therapy.
1.Introduction
Endometrial malignancies can be categorized into two
main groups based on the cell of origin: (i) endometrial
carcinoma including carcinosarcoma and (ii) endometrial
stromal sarcoma. Endometrial carcinomas show a broad
spectrum of phenotypes which show various histologic
appearances for example, endometrioid, serous, mucinous,
squamous, urothelial, or clear cell, reﬂecting the diﬀerentia-
tion potential of the m¨ ullerian epithelium and the diﬀerence
in the tumorigenetic pathways of each tumor type. Women
with an inherited predisposition for endometrial neoplasm
have been reported, associated with autosomal dominant
disorders such as hereditary nonpolyposis colorectal carci-
noma (HNPCC) and Cowden syndrome. Some endome-
trial carcinomas undergo mesenchymal diﬀerentiation and
are termed carcinosarcomas (formerly termed malignant
mixed m¨ ullerian tumors). Pathogenetically and clinically,
two distinct forms of endometrial adenocarcinoma, type I
and type II, have been described. The molecular alterations
driving endometrial carcinogenesis may follow a sequence
similartoVogelstein’s model fortheprogressionofcolorectal
adenoma to carcinoma. This process is accompanied by
stepwise genetic changes of oncogenes and tumor suppressor
genes. Endometrial stroma may give rise to neoplasms that
resemble normal endometrial stromal cells. The spectrum of
endometrial stromal tumors ranges from the benign stromal
nodule to the malignant endometrial stromal sarcoma. An
oncogenic fusion gene, JAZF1/JJAZ1 plays a signiﬁcant role
in tumor development of endometrial stromal sarcomas [1].
2.MolecularProﬁlingofEndometrial
Carcinoma
2.1. Dualistic Model of Endometrial Tumorigenesis. Endome-
trial carcinoma is the most common malignant neoplasm
of female genital tract in developed countries [2]w i t ha n
estimated 42,160 new cases diagnosed in the United States
for 2009 [3]. Approximately 90% of cases of endometrial
carcinoma are sporadic, whereas the remaining 10% of cases
are hereditary [4]. Clinically, the patients with endometrial
carcinomas most often present with abnormal uterine bleed-
ing. In advanced stages, patients may complain of pelvic
pain, reﬂecting spread of the carcinoma. Bokhman [5]ﬁ r s t
described the pathogenetic classiﬁcation of 2 diﬀerent types
of endometrial carcinoma, designated as type I and type
II carcinomas, according to the determination of biological
properties of the tumor, its clinical course, and the prognosis
of the disease.2 Obstetrics and Gynecology International
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Figure 1: The prototypes for the dualistic model of endometrial carcinoma. Type I endometrioid endometrial carcinoma shows glands
lined by stratiﬁed neoplastic columnar cells (a), ×100; and type II serous carcinoma showing papillary structures and high nuclear grade
(b), ×100.
2.1.1. Type I (Endometrioid Endometrial Carcinoma) [1, 2, 4–
13]. Type I carcinomas represent the majority of sporadic
cases of endometrial carcinoma, accounting for 70–80% of
new cases [4, 9–12] which occur predominantly in pre-
and perimenopausal women. These cancers are typically
of endometrioid type (Figure 1(a)). Risk factors include
obesity, hyperlipidemia, and hyperestrogenism for example,
anovulation, nulliparity/infertility, late onset of menopause,
and endometrial hyperplasia. The tumors in this category
are generally low-grade, low-stage, and indolent. They
commonly express estrogen and progesterone receptors [2,
4–11]. The rare mucinous carcinomas are also considered
type I carcinomas because they usually express estrogen
and/orprogesteronereceptorsandareoflowhistologicgrade
[10, 11].
2.1.2. Type II (Nonendometrioid Endometrial Carcinoma) [1,
2, 4–13]. Type II carcinomas are less common, accounting
for 10–20% of endometrial carcinoma [4, 6]. They are
nonendometrioid in diﬀerentiation, most frequently papil-
lary serous (Figure 1(b)) and less frequently clear cell, have
high-grade histology, typically arise in an atrophic endome-
trial background, and often have deep myometrial penetra-
tion. They usually occur at an older age, approximately 5–
10 years later than type I tumors. There is no relationship
to estrogen stimulation. Clinically, type II cancers have
an aggressive behavior, with a high frequency of distant
spread to pelvic lymph nodes. Small cell, undiﬀerentiated
and squamous cell carcinomas may also be encountered
among type II carcinomas, but little is known about their
tumorigenesis [11]. The clinical and pathological features of
the two types of endometrial carcinomas are summarized in
Table 1.
2.2. Common Molecular Genetic Alterations in Dualistic
Model. Evidence for divergent molecular alterations sup-
porting the dualistic model of endometrial tumorigenesis
became available approximately 10 years after Bokhman’s
description of the clinical and pathologic features. The
two distinct histological types of carcinomas are associated
with genetic alterations of independent sets of genes. These
genetic changes may occur singly or in various combinations
which diﬀer between individual cases [9].
Westin and colleague [14] described that expression of
estrogen-induced genes, RALDH2, EIG121, SFRP1, SFRP4,
IGF-1,a n dIGF-IR, tend to be highest in the well-to-
moderately diﬀerentiated endometrioid carcinoma. This
ﬁnding supports the partitioning of endometrial carcinoma
into two distinct groups by traditional estrogen-related
classiﬁcation. According to this model, normal endometrial
cells would transform into endometrioid endometrial car-
cinoma through 5 diﬀerent molecular changes, including,
mutations of PTEN, PIK3CA, KRAS,a n dCTNNB1 (β-
catenin) genes and microsatellite instability (MSI) while
non-endometrioid endometrial carcinoma is frequently
related to alterations of p53 and chromosomal instability
[7, 8, 15, 16]. Non-endometrioid endometrial carcinoma
frequently demonstrates high-ordered aneuploidy and has
an intact mismatch repair (MMR) mechanism [12]. Fur-
thermore, none of the ﬁve main alterations of endometri-
oid endometrial carcinoma (mutations of PTEN, PIK3CA,
KRAS,a n dCTNNB1 genes and MSI) plays a major role
in non-endometrioid endometrial carcinoma. However, in
many endometrial carcinomas exhibit overlapping clinical,
morphologic,immunohistochemical,andmolecularfeatures
of the both types of carcinoma for example, a subset
of endometrioid endometrial carcinoma is found with a
background of atrophic endometrium or papillary serous
carcinoma may occasionally develop from a pre-existing
endometrioid endometrial carcinoma and may share histo-
logical and genetic features [8–10]. Matias-guiu et al. [8]
described the development of non-endometrioid endome-
trial carcinoma through these possible pathways: (i) de novo,
through p53 mutations, loss of heterozygosity (LOH) at
several loci, and some other still unknown gene alterations;
or (ii) through dediﬀerentiation of a pre-existing endometri-
oid carcinoma. These dediﬀerentiated non-endometrioid
endometrial carcinomas exhibit overlapping features with
type I endometrioid endometrial carcinoma [8].Obstetrics and Gynecology International 3
Table 1: Clinical and pathological characteristics of type I and type II endometrial carcinoma [1, 2, 4–13].
Type I Type II
Proportion of endometrial carcinomas 4/5 1/5
Menstrual status Pre- and perimenopausal Postmenopausal
Endocrine-metabolic disturbance Present Absent
Estrogen-associated Yes No
Background endometrium Hyperplasia Atrophy
Histological type Endometrioid Serous, clear cell
Tumor grade Low High
Depth of myometrial invasion Superﬁcial Deep
Behavior Stable/indolent Progressive/aggressive
Comparison of the major genetic alterations between
type I and type II endometrial carcinomas is shown in
Table 2.
Moleculargeneticalterationshavebeenextensivelyinves-
tigated in endometrioid and papillary serous adenocarci-
nomas of the endometrium. These two tumor types are
characterized by distinctive molecular alterations, and their
tumorigenesis follow separate pathways.
2.3. Molecular Pathology of Endometrioid Carcinomas
2.3.1.PTEN. Themostfrequentlyalteredgeneinendometri-
oid endometrial carcinoma is PTEN (phosphatase and
tensin homologue deleted from chromosome 10), also
called MMAC1 (mutated in multiple advanced cancers 1).
PTEN behaves as a tumor suppressor gene, is located on
chromosome 10q23.3 and encodes a lipid phosphatase that
antagonizes the PI3K/AKT pathway by dephosphorylating
PIP3, the product of PI3K. This lipid molecule is an impor-
tant second messenger that regulates the phosphorylation
of a protein termed AKT, also known as protein kinase B.
Decreased PTEN activity causes increased cell proliferation
and survival through modulation of signal transduction
pathways.
PTEN may be inactivated by several mechanisms such as
mutation, LOH, and promoter hypermethylation. Somatic
PTEN mutations are common in endometrial carcinoma,
and they are almost exclusively restricted to endometrioid
endometrial carcinomas, occurring up to 83% of them [1,
4, 11, 12]. Germline mutations of PTEN are responsible for
Cowden syndrome [9, 12]. PTEN may be also inactivated
by deletion, as shown by LOH in 40% of endometrial
carcinomas [7–9,17]. Promoter hypermethylation leading to
PTEN inactivation, is found in about 20% of tumors, most
of which are high-stage [10].
PTEN mutations have been detected in 15–55% of
endometrial hyperplasias with and without atypia [9, 13].
Interestingly, concordance between MSI status and PTEN
mutations has been found; the mutations occur in 60–86%
of MSI-positive endometrioid endometrial carcinoma but
in only 24–35% of the MSI-negative cases [7–9, 13, 17].
This suggests that PTEN could be a target for mutations
in the context of DNA repair deﬁciency [13]. In addi-
tion, identical PTEN mutations have been also identiﬁed
in hyperplasias coexisting with MSI-positive endometrioid
endometrial carcinoma, which suggests that PTEN muta-
tions are early events in their development [8]. On the
other hand, identical PTEN mutations have been detected in
MSI-negative endometrial hyperplasia with coexisting MSI-
positive endometrioid endometrial carcinomas. Thus, some
PTEN mutations may precede MSI, and coexistence of both
alterations does not necessarily mean a cause-eﬀect relation-
ship [9]. Evaluation of PTEN inactivation in endometrial
carcinoma precursor lesions by PTEN immunostaining has
been proposed. However, commercially available antibod-
ies (e.g., clone 10P03, 28H6, polyclonal, 6H2.1) do not
have statistically signiﬁcant associations with the molecular
genetic alterations [7, 9, 19]. Some data suggest that PTEN
is associated with younger age, low stage, endometrioid
histology,lowhistologicgrade,andfavorableprognosis(78%
5-year survival for patients without mutations, compared
with 95% and 93% for patients with one or more mutations,
resp.) [7, 9]. In addition, recent data suggest that only PTEN
mutations outside exons 5–7 may predict favorable survival,
independent of the clinical and pathological features of the
tumors [9].
2.3.2. PIK3CA. The PIK3CA (p110α catalytic subunit
of PI3K) gene locates on chromosome 3q26.32.
Phosphatidylinositol-3-kinase (PI3K) is heterodimeric
lipid kinase consisting of a catalytic subunit (p110) and a
regulatory subunit (p85) in PI3K/AKT signaling pathway.
This pathway is frequently activated in endometrial
carcinoma through various genetic alterations and their
combinations. Activation of PI3K produces the second
messenger PIP3 which subsequently activates various
down-stream pathways such as AKT. This regulation
involves suppression of apoptosis and enhancement of cell
proliferation [9]. PIK3CA activation is reported in 26–36%
of endometrial carcinoma and may coexist with PTEN
(15–27%) [7, 9, 12, 15, 20]a n dKRAS mutations [9, 15, 20]
suggesting that the PIK3CA mutations cooperate with these
alterations in malignant transformation [16]. Mutations
in AKT family members and their correlation with other
gene alterations are found in endometrial carcinoma,4 Obstetrics and Gynecology International
Table 2: Genetic alterations of type I and type II endometrial carcinomas, reported in percentages (references).
Type I Type II
PTEN inactivation Up to 83% [1, 4, 11, 12] 11% [1, 2, 12]
PIK3CA mutation 26–36% [7, 9]5 % [ 7]
KRAS mutation 10–30% [1, 2, 4, 7–12, 17] 0–10% [2, 12]
β-catenin /CTNNB1 mutation 14–44% [7, 8]0 – 5 % [ 1, 7, 10, 11]
Microsatellite instability 20–45% [1, 7–10] 0–11% [8, 9]
p53 mutation 10–20% [1, 4, 6, 7, 10, 11, 13, 17, 18] 90% [1, 2, 4, 6, 7, 10–13, 17]
HER2/neu ampliﬁcation 10–30% [1, 4, 10, 17] 18–80% [13]
p16 inactivation 10% [1, 4, 7, 10, 11] 40–45% [4, 7, 10]
E-cadherin loss 10–20% [1, 4, 7, 10, 11] 60–90% [4]
including AKT2 (D399N), AKT2 (D32H) and AKT3
(E438D) mutations. Mutations of AKT3 (E438D) also have
ampliﬁcationofandamutationin PIK3CA[21].AKT1E17K
mutation is not associated with either PTEN or PIK3CA
genomic alteration [21]. In vitro studies showed that
activating mutations of PIK3CA in combination with PTEN
mutations led to an additional increase in phosphorylated
AKT when compared with cells with only inactivated PTEN
[6]. Some investigators have claimed that PIK3CA mutations
are mutually exclusive of PTEN mutations, suggesting that
tumorigenic signaling through this pathway can occur
either through activation of PIK3CA or inactivation of
PTEN [9]. Recently, interactions between the PI3K/AKT
and p53 signaling pathways have been described in which
activation of the PI3K/AKT pathway through PTEN or
PIK3CA mutations, together with p53 inactivation, results
in malignant transformation [15]. Moreover, patients with
dysregulation of PI3K/AKT signaling pathway and p53
alterations had shorter survival than patients with only
p53 alterations [15] .M u t a t i o n sw e r em o r ec o m m o ni n
mixed endometrioid-nonendometrioid adenocarcinomas
(44%) than in pure endometrioid adenocarcinomas
(28%) or pure nonendometrioid adenocarcinomas
(21%) [15]. In fact, PIK3CA mutations are usually
missense and cluster in exons 9 (helical domain) and
20 (kinase domain). The tumors carrying exon 9 PIK3CA
mutations are more likely to be low-grade carcinomas; in
contrast, carcinomas with exon 20 mutations or PIK3CA
mRNA overexpression are often high-grade carcinomas
associated with myometrial invasion and tended to have
lymphovascular invasion [15]. Furthermore, in high-grade
endometrioid adenocarcinomas and mixed carcinomas,
PIK3CA m u t a t i o n si ne x o n2 0c o e x i s tw i t hp53 alterations
morefrequentlythaninnonendometrioidadenocarcinomas.
However, PIK3CA mRNA overexpression occurs in concert
with p53 alterations only in nonendometrioid endometrial
carcinomas [15]. PIK3CA mutations did not correlate with
MSI or β-catenin/CTNNB1 mutations [9, 18]. PIK3CA
mutations, particularly exon 20 mutations or PIK3CA
mRNA overexpression, are frequent in endometrioid
endometrial carcinoma in association with invasion and
adverse prognostic factors such as blood vessel invasion
[7, 15].
2.3.3. KRAS. KRAS encodes a member protein of the
small GTPase superfamily and is involved in signal trans-
duction pathways between cell surface receptors and the
nucleus. KRAS mutations have been identiﬁed in 10–30%
of endometrioid endometrial carcinomas [1, 2, 4, 7–12, 17]
while some investigators have reported an almost complete
absence of KRAS mutations in serous and clear cell carci-
nomas of endometrium [8]. Some studies found a higher
frequency of KRAS mutations in MSI-positive carcinomas
than in MSI-negative tumors [8–10, 16] suggesting that both
events may occur simultaneously before clonal expansion
[10, 13]. KRAS mutations were detected in endometrial
hyperplasias at a similar rate to that observed in endometri-
oid endometrial carcinomas, suggesting that KRAS muta-
tions are early events in endometrial carcinogensis [9, 13].
No relationship has been found between KRAS mutations
and tumor stage, histologic grade, depth of myometrial inva-
sion, age, or clinical outcome in endometrioid endometrial
carcinomas [9].
2.3.4. β-Catenin (CTNNB1). The β-catenin gene (CTNNB1)
maps to 3p21. It appears to be important in the functional
activities of both APC (adenomatous polyposis coli) and
E-cadherin. It is a component of the E-cadherin-catenin
unit, essential for cell diﬀerentiation and maintenance of
normal tissue architecture and also plays an important role
in Wnt signal transduction pathway. Mutations in exon 3 of
CTNNB1resultinstabilizationofaproteinthatresistsdegra-
dation, leading to nuclear accumulation of β-catenin, have
been described in endometrioid endometrial carcinoma.
The accumulation of β-catenin can be demonstrated by
immunostaining. Several studies have analyzed endometrial
carcinomas showing that nuclear accumulation of β-catenin
is signiﬁcantly more common in endometrioid lesions (31–
47%) compared with nonendometrioid histology (0–3%)
[4]. By comparison in colonic adenocarcinomas, elevated β-
cateninlevelscausedbymutationsinCTNNB1orAPCresult
in activation of the Wnt/β-catenin/LEF1 pathway through
a LEF1 binding site in the cyclin D1 promotor, triggering
cyclin D1 gene expression, and subsequently, uncontrolled
progression of tumor cells into the cell cycle [8, 12].
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the matrix metalloproteinase-7 that would have a role in
the establishment of the microenvironment necessary for the
initiation and maintenance of growth of the primary tumor
and metastasis [8, 12]. The reported frequency of CTNNB1
mutations in endometrioid endometrial carcinoma ranges
from 14–44% [7, 8]. They seem to be independent from
the presence of MSI and the mutations of PTEN and
KRAS, suggesting that the Wnt pathway may play an
independent role in endometrial cancer [10, 13]. In all cases,
the mutations were homogeneously distributed in diﬀerent
areas of the tumors suggesting that they play a role in
early steps of endometrial tumorigenesis. Alterations in β-
catenin have been reported in endometrial hyperplasias with
squamous metaplasia [7, 9]. Although there was a good cor-
relation between CTNNB1 mutations and β-catenin nuclear
immunostaining, the presence of cytoplasmic and nuclear β-
catenin immunoreactivity in some endometrial carcinomas
without CTNNB mutation suggests that the changes of
other genes in the Wnt/β-catenin/LEF-1 pathway may be
responsible for the stabilization and putative transcription
activator role of β-catenin [7, 8]. Endometrioid endometrial
carcinomas with CTNNB1 mutations are characteristically
early stage tumors associated with favorable prognosis [7, 9].
Two members of the secreted frizzled-related protein (SFRP)
family, SFRP1 and SFRP4, were more frequently down-
regulated in MSI-positive carcinomas compared with MSI-
negative carcinomas. This down-regulation was associated
with frequent promoter methylation of SFRP1 and led to
an activation of the β-catenin pathway. In addition, the
Wnt-target ﬁbroblast growth factor 18 was up-regulated in
endometrioid carcinomas with MSI compared with normal
endometrium [1].
2.3.5. Microsatellite Instability. Microsatellite DNA sequen-
ces are polymorphic, short-tandem repeats distributed
throughout the genome. The most common microsatellite
in human is a dinucleotide repeat of CA, (CA)n, and there
are 50,000 to 100,000 (CA)n repeats scattered in the human
genome [8, 9]. Microsatellite instability (MSI) is a condition
manifested by damaged DNA because of defects in normal
DNA repair process. Mammalian mismatch repair (MMR)
genes encode for nine proteins (MLH1, MLH3, PMS1,
PMS2, MSH2, MSH3, MSH4, MSH5, and MSH6) that
interactwitheachothertoformcomplexesandheterodimers
that mediate distinct functions in MMR-related system. This
repair process plays a central role in promoting genetic
stability by repairing DNA replication errors, inhibiting
recombination between non-identical DNA sequences and
participatinginresponsestoDNAdamage.MSIisacommon
genetic abnormality that has been detected in 20–45% of
sporadic endometrioid endometrial carcinoma [7–10]. In
addition, MSI in nonendometrioid endometrial carcinomas
has been reported (0–11%) [8, 9], particularly in mixed
endometrioid and serous carcinomas, but not in pure
serous carcinomas [10]. In sporadic endometrial carcinoma,
epigenetic cause of MSI is more common involving MLH1
promotor hypermethylation which is the main cause of
MMR deﬁciency [7–9, 13, 15]. This epigenetic inactivation
usuallyoccursin atypical hyperplasia,most of whichcoexists
with carcinomas. Thus, MLH1 hypermethylation is an early
event in the pathogenesis of endometrioid endometrial
carcinoma, which precedes the development of MSI [7–9,
15]. The remaining unmethylated MLH1 cases reveal MSH2
mutations (15%) and MSH6 mutations (60%), of which
almost half are germline mutations. Thus, MSH6 mutations
seem to be a frequent cause of MSI [11, 12]. Tumors with
MSI of CpG island methylation in the promoter region have
been identiﬁed in some other genes, for example, p16,PTEN,
and E-cadherin (CDH1), suggesting altered methylation
may be a coexisting independent early change [9]. The
presentation of some small short-tandem repeats such as
mononucleotide repeats located within the coding sequence
of important genes for example, transforming growth factor
β receptor type II (TGF-βRII), BAX, insulin-like growth
factor II receptor (IGFIIR), MSH3, MSH6, caspase-5,a n d
PTEN may promote MSI-positive endometrial carcinoma
[8, 9]. Secondary mutations at one or more mononucleotide
tracts found in 72.7% of tumors with MSI, are responsible
for tumor progression [7–9]. International Federation of
Gynecology and Obstetrics (FIGO) grade has been found to
behigherinendometrioidendometrialcarcinomaswithMSI
in some, but not all studies, similar to the well-established
association between MSI and high-grade colorectal carci-
nomas [16]. By multivariate analysis, a signiﬁcant corre-
lation between MSI-positive tumors and tumor-inﬁltrating
lymphocytes in endometrioid endometrial carcinoma was
found: 40 tumor-inﬁltrating lymphocytes/10 high power
ﬁelds has a sensitivity of 85% and a speciﬁcity of 46% in
predicting MSI [16].
2.4. Molecular Pathology of Nonendometrioid Carcinomas
2.4.1. p53. The p53 t u m o rs u p p r e s s o rg e n el o c a t e st o
chromosome 17p13.1. While p53 mutations occur in 90%
of non-endometrioid endometrial carcinoma, they are only
present in 10–20% of endometrioid endometrial carcinoma,
which are mostly high-grade [7, 18]. The abnormal p53
expression has been found in 11% of grade 1 endometrioid
endometrial carcinoma [18]. This ﬁnding supports that
p53 mutations may inﬂuence progression of endometrioid
endometrial carcinomas to non-endometrioid endometrial
carcinomas [9]. In fact, p53 mutation is the most charac-
teristic genetic alteration of non-endometrioid endometrial
carcinomas [9, 10] and may be useful in their distinction
from endometrioid endometrial carcinomas [22]. In p53
positive endometrioid endometrial carcinoma, p53 protein
accumulation may be secondary to changes in its upstream
regulatory proteins rather than the p53 gene itself. Several
genes, including MDM2 and p14 AR, that regulate p53 levels
have been shown to cause detectable levels of p53 in the
absence of p53 mutation. Alternatively, nonspeciﬁc DNA
damage such as that induced by irradiation is also known
to induce accumulation of wild-type p53 [12]. In normal
cells, p53 is rapidly degraded and thus cannot be detected by
immunostaining. p53 mutations produce a non-functional
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immunostaining [11, 18]. However, loss of function of
p53 resulting from LOH may not correlate with protein
overexpression. In addition, frameshift mutations and stop
codons lead to a truncated protein, which is not detected by
antibodies and leads to negative immunohistochemistry [11,
18] After DNA damage, nuclear p53 accumulates and causes
cell cycle arrest by inhibiting cyclin D1 phosphorylation
of the Rb gene and thereby promoting apoptosis [9, 13].
Overexpression of p53 is associated with high histological
grade and advanced stage as well as unfavorable prognosis
[9, 18]. Endometrial intraepithelial carcinoma (EIC), the
putative precursor lesion to serous carcinomas [4, 13, 18, 22,
23], characterized by replacement of the surface epithelium
by malignant cells exhibiting cytological features similar to
those of serous carcinoma [9, 23]. EIC has been reported
in nearly 90% of uteri containing serous carcinoma that is
often extensive and multifocal [23]. Mutations of p53 are
also found in 75–80% of EIC. It is postulated that mutation
in one allele occurs early during the development of serous
carcinoma, and loss of the second normal allele occurs late in
the progression to carcinoma [4]. p53 mutations are almost
always associated with aneuploidy and do not seem to occur
with PTEN mutations in the same tumor [10, 11].
2.4.2. HER2/neu. Epidermal growth factor receptor II or
HER2/neu is an oncogene that codes for a transmembrane
receptortyrosinekinaseinvolvedincellsignalingandlocated
at the long arm of human chromosome 17q12. HER2/neu
overexpression or ampliﬁcation is more frequently found
in non-endometrioid endometrial carcinoma (18–80%) [13]
than in grade 2 and 3 endometrioid carcinoma (10–30%)
[7, 9, 10] and has been associated with adverse prognostic
parameters including advanced stage, high histologic grade,
and low overall survival [9, 13].
2.4.3. p16. p16 plays an important role in regulating the cell
cycle. It is a tumor suppressor gene located on chromosome
9p21 [10]. p16 inactivation can lead to uncontrolled cell
growth. Inactivation of p16 is more frequent in non-
endometrioid endometrial carcinoma (40–45%) than in
endometrioid endometrial carcinoma (10%) [4, 7, 10]. The
underlying mechanism is unclear [7, 11], because neither
promoter hypermethylation nor deletion or mutation is
frequently found [11]. Loss of p16 expression is correlated
with KRAS and p53 mutations and is associated with high
stage, high grade, and poor survival [10].
2.4.4. E-Cadherin. Cadherins are a family of adhesion
molecules essential for tight connection between cells. E-
cadherin is encoded by CDH1 gene and locates on chromo-
some 16q22.1. It is thought to be a tumor suppressor gene,
the loss of which has been demonstrated to promote tumor
invasion and metastasis. Decreased expression of E-cadherin
is frequent in endometrial carcinoma and may be caused by
LOH or promotor hypermethylation. LOH at 16q22.1 is seen
inalmost60%ofnon-endometrioidendometrialcarcinoma,
but in only 22% of endometrioid endometrial carcinoma
[7]. In endometrial carcinoma, partial or complete loss of E-
cadherin expression correlates with aggressive behavior [9].
Among type II carcinomas, clear cell carcinomas seem
to follow a separate pathway that shows some overlap with
serousandendometrioidcarcinomas.p53mutationsareonly
present in about 30–40% of clear cell carcinomas compared
to 90% of serous carcinomas. However, the frequency of MSI
and PTEN alterations in clear cell carcinoma is higher than
in serous carcinoma (15% versus <5 for MSI and 30% versus
10% for PTEN) but lower compared with endometrioid
carcinoma (20–40% and 35–50%, resp.) [24]. A recent
molecularstudydemonstratedthatthemajorityofpureclear
cell carcinomas do not show mutations in either PTEN or
p53, the most commonly altered genes in type I and type
II tumors, respectively. These ﬁndings suggest that clear cell
carcinoma may arise through a distinct pathologic pathway
[6].
2.4.5. Apoptosis Resistance in Endometrial Carcinoma. Sev-
eral of the molecular abnormalities that have been detected
in EC may be associated with apoptosis deregulation.
Apoptosis can be initiated by two main mechanisms: (i)
the “intrinsic pathway” activated by released mitochondrial
proteins, such as cytochrome-c; and (ii) the “extrinsic
pathway” activated by ligand-bound death receptors such as
tumor necrosis factor (TNF), Fas or TNF-related apoptosis
including ligand (TRAIL) receptors. Some studies have
shown that cellular apoptosis susceptibility (CAS)g e n e ,
BCL2, BAX, and caspase-3 are apparently involved in the
progressive deregulation of proliferation and apoptosis,
leading from simple and complex endometrial hyperplasia
to adenocarcinoma. As described above, PTEN antagonizes
thePI3K/AKTpathwaybydephosphorylatingPIP3,resulting
in decreased translocation of AKT activation. Thus, loss
of PTEN function leads to increased levels of phospho-
AKT, activation of anti-apoptotic protein, and cell cycle
progression[9].NF-κB,frequentlyactivatedinendometrioid
endometrial carcinomas, may inhibit apoptosis by activation
of target genes such as FLIP and Bcl-XL. Furthermore,
there are reports that apoptosis-related protein survivin
is frequently overexpressed in endometrial carcinomas [7,
9] and correlates inversely with PTEN expression [9].
Where widespread genetic abnormalities exist that cannot
be corrected, MMR proteins initiate apoptosis as a more
energy eﬃcient option of universal genomic preservation
[16]. MMR deﬁciency lowers the apoptotic rate, leading a
survival advantage to the mutated cells [16].
2.4.6. cDNA Array Studies. cDNA analyses have demon-
strated that the expression proﬁling of endometrioid
endometrial carcinoma is diﬀerent from that of non-
endometrioid endometrial carcinoma. These studies have
identiﬁed gene signatures speciﬁc for non-endometrioid
endometrial carcinomas as well as genes speciﬁcally up-
or down-regulated in endometrioid endometrial carcino-
mas when compared with normal endometrium. Intestinal
trefoil protein, TFF3, AGR2 developmental gene, estrogen-
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and MSX2 were signiﬁcantly up-regulated in endometri-
oid endometrial carcinomas, while increased expression of
FOLR, genes involved in the regulation of mitotic spindle
checkpoint (STK15, BUB1, CCNB2), IGF2, PTGS1 and p16
were seen in non-endometrioid endometrial carcinomas.
STK-15 alsoknown asBTAK, Aurora-A,is a serine/threonine
kinase which is essential for chromosome segregation and
centrosome functions [7, 9]. Overexpression of STK15
induces increased numbers of centrosomes, aneuploidy, and
malignant transformation. One study found STK15 ampli-
ﬁcation in 9 of 15 (60%) non-endometrioid endometrial
carcinomas but in none of endometrioid endometrial car-
cinomas [9]. Furthermore, a diﬀerent expression proﬁle was
also found between endometrial carcinoma associated with
MSI and stable endometrial carcinoma. SFRP1 and SFRP4
were more frequently down-regulated in endometrial carci-
noma with MSI. One study compared the expression proﬁles
of similar histological subtypes of ovarian and endometrial
carcinomas,andshowedthatclearcellcarcinomashadavery
similar proﬁle, regardless of the organ of origin. In contrast,
diﬀerences were seen when comparing endometrioid and
serous carcinomas of ovarian and endometrial origin [7].
3.GeneticChanges inEndometrial
Carcinogenesis(ProgressionModels) of
Endometrioid and SerousCarcinomas,
IncludingMolecular Changes of
PremalignantDisease(Hyperplasia/EIC)
By epidemiological and molecular evidence, endometrial
hyperplasia represents a true precursor lesion for endometri-
oid endometrial carcinomas, whereas non-endometrioid
endometrial carcinomas are frequently associated with
endometrial intraepithelial carcinoma (EIC) [13].
3.1. Progression Model for Endometrioid (Type I) Carcinomas.
A progression model of endometrioid carcinoma resembling
the Vogelstein progression model for colorectal carcinoma
has been proposed. This hypothesis is supported by the
evidence that (i) some of the genetic alterations found in
endometrioid endometrial carcinomas are already present
in atypical hyperplasia, (ii) increased genetic alterations are
f o u n di nw e l l - d i ﬀerentiated endometrioid carcinoma com-
pared with atypical hyperplasia, (iii) the number of genetic
alterations increase according to higher histologic grade,
and (iv) more chromosomal imbalances are identiﬁed in
endometrial carcinoma compared with atypical hyperplasia,
using comparative genomic hybridization (CGH) [11].
Most simple hyperplasias and a subset of complex
hyperplasias are polyclonal and considered reactive processes
due to hyperestrogenism, which may regress through pro-
gesterone therapy [11, 23]. In contrast, most atypical hyper-
plasias are monoclonal. A subset of complex hyperplasia
without atypia has been reported to be monoclonal. In addi-
tion, the number of chromosomal aberrations in complex
hyperplasia is signiﬁcantly higher than simple hyperplasia
and close to the number found in atypical hyperplasia.
Most of the genetic alterations identiﬁed in endometrioid
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Figure 2: A progression model for endometrioid carcinoma.
Tumor initiation and progression are characterized by acquisition
of various molecular alterations. PTEN alterations appear central
to the initiation of proliferative lesions that then acquire mutations
in other cancer-causing genes (e.g., DNA mismatch repair genes,
KRAS, β-catenin) in the carcinogensis. An alternative pathway
bypasses atypical hyperplasia and low-grade carcinoma to high-
grade carcinoma by p53 mutation and HER2/neu ampliﬁcation.
NE, normal endometrium; EH, endometrial hyperplasia without
hyperplasia, AH, atypical endometrial hyperplasia; EIC, endome-
trial intraepithelial carcinoma; LG-ECC, low grade endometri-
oid endometrial carcinoma; HG-ECC, high grade endometrioid
endometrial carcinoma.
endometrial carcinoma seem to occur very early in the
development of endometrioid carcinoma, although it is
not clear which alterations are associated with the earliest
changes of malignant transformation and progression to
neoplasia [10, 11]. In atypical hyperplasia, alterations of
PTEN, β-catenin, KRAS, and MSI are present, with PTEN
inactivation occuring in about 50% of the cases. However,
PTEN and KRAS mutations seem to occur earlier, since
they were found in simple hyperplasia, partially associated
with monoclonality. PTEN inactivation has been reported
in normal endometrial glands but its signiﬁcance is yet
unknown [11]. The inactivation of E-cadherin gene by
methylation seems to play a role during progression of
endometrioid carcinoma, since it is most frequently found
in grade 3 and least frequently in grade 1 tumors [10].
Furthermore, p53 mutations, HER2/neu overexpression or
ampliﬁcation, and p16 inactivation are considered in late
events during carcinogenesis of endometrioid carcinoma,
since they are predominantly identiﬁed in grade 3 tumors,
butrarelyingrade1tumors,andareabsentinatypicalhyper-
plastic lesions. Hypothetically, p53 mutations and HER2/neu
ampliﬁcation might also be early events in de novo poorly
diﬀerentiated endometrioid carcinomas [10, 11]( Figure 2).
Endometrial pre-cancers (e.g., EIC) have been postulated
to share common genetic alterations with endometrioid
endometrialcarcinoma,includingPTEN mutationsandMSI
[13].
3.2. Progression Model for Nonendometrioid (Type II) Car-
cinomas. Mutations of p53 were found in approximately
80% of EIC, but in contrast to most serous carcinomas,
there is no LOH at the locus TP53. Thus, it is hypothesized
that p53 mutation of one allele occurs early, whereas loss
of the normal second allele accompanies progression into
serous carcinoma [10, 11]. The alterations of E-cadherin,8 Obstetrics and Gynecology International
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Figure 3: A progression model for nonendometrioid (type II)
carcinomas. p53 mutations play a critical role in the conversion of
atrophic endometrium to an intraepithelial form of serous carci-
noma. NE, normal endometrium; EIC, endometrial intraepithelial
carcinoma; NEEC, non-endometrioid endometrial carcinoma.
p16,a n dHER2/neu seem to aﬀect the progression from
EIC to serous carcinoma [10]. Another group hypothesized
that serous carcinoma may develop from endometrioid
carcinoma through p53 mutation based on ﬁndings in
mixed endometrioid and serous carcinomas. Early genetic
alterations during carcinogenesis are not clear, as these
authors presented no data for EIC [10, 11]( Figure 3).
4.HereditaryEndometrial Carcinoma
Hereditary endometrial carcinoma has been found in 2–5%
of endometrial cancer [24]. Hereditary nonpolyposis colon
cancer (HNPCC), also known as Lynch syndrome or cancer
familysyndrome,accountsforthemajorityofinheritedcases
[24].Itis anautosomaldominant syndrome thatpredisposes
its carriers to multiple malignancies particularly colorectal,
and endometrial carcinomas [25], caused by a germline
mutation in one of the DNA MMR genes occurring in 30–
60% of cases [8, 9]. Endometrial carcinoma is the most
common extracolonic malignancy in patients with HNPCC.
In women with HNPCC, the incidence of endometrial
carcinoma equals or exceeds that of colorectal carcinoma,
compared with 1% in the general population [26], and in
more than 50% of HNPCC cases, these women present with
a gynecological cancer as their ﬁrst or “sentinel” malignancy
[25]. The frequency of germline DNA MMR gene mutations
among unselected patients with endometrial carcinoma has
been found to be 1.8–2.1%, which is similar to the frequency
of HNPCC in colorectal carcinoma [25]. Patients with
endometrial carcinoma in the HNPCC population have
an inherited germline mutation in MLH1, MSH2, MSH6,
or PMS2 (ﬁrst hit) but endometrial carcinoma develops
only after the initiation of a deletion or mutation in the
contralateral MLH1, MSH2, MSH6,o rPMS2 allele (second
hit)inendometrialcells[7,8]. Once the 2 hits have occurred,
the deﬁcient MMR function of MLH1, MSH2, MSH6,o r
PMS2 causes the acquisition of MSI and subsequent tumor
development [7–9]. Unlike HNPCC associated colorectal
carcinoma, which appears to frequently have MLH1 and
MSH2 mutations, endometrial carcinomas have a higher
probability of MSH2 and MSH6 mutations [13, 25]. Women
with HNPCC who carry MSH2 and MSH6 mutations have
a higher chance to present initially with endometrial rather
than colorectal cancer [16]. MSI has been detected in 75%
of endometrial carcinoma associated with HNPCC [8, 9].
Many studies have shown that MSI is associated with
endometrioidhistologictype.However,14–21%ofHNPCC-
associated endometrial carcinomas are non-endometrioid,
but only 3.3–4.5% of sporadic MSI tumor [16]. Women
with an inherited predisposition for endometrial neoplasia
tend to develop the disease 10 years earlier than the general
population [9]. There is 18–23% incidence of HNPCC
syndrome in endometrial carcinoma patients younger than
50 years old [16]. In addition to endometrial carcinoma
arising from HNPCC, occasional families show clustering of
endometrial cancer alone, without colon or other cancers.
This group was termed as “familial site-speciﬁc endometrial
cancer” [10]. Loss of protein expression seems to occur
frequently for both MLH1 and MSH2 in endometrial
hyperplasia and is considered an early event during tumor
development [11]. PTEN inactivation by mutation seems
to also be involved in tumorigenesis, since it occurs in
about 90% of type I carcinomas [11]. Currently, there are
no data to suggest that the prognosis for women with
HNPCC-associated endometrial cancers is either better or
worse than for women with sporadic cancers [16, 24]. In
one study, endometrial carcinoma in HNPCC kindreds was
a cause of death in 12% of cases; in 61% of cases these
patients had a second primary malignancy; and 15% of
cases had more than 2 additional primary cancers. Nieminen
et al. [26] studied serial endometrial biopsy samples taken
during a 10-year followup of HPNCC mutation carriers
and found abnormal MMR protein expression, MSI, or
tumor suppressor promotor hypermethylation in various
endometrial histologies, including normal and hyperplastic
endometria. The most frequently methylated genes were
CDH13, RASSF1A,a n dGSTP1. These defects in MMR and
m e t h y l a t i o na p p e a r e du pt o1 2y e a r sb e f o r ee n d o m e t r i a l
carcinoma [26].
PTEN hamartoma tumor syndrome, caused by a
germline mutation in PTEN gene on chromosome 10q,
comprises a group of disorders including Cowden syndrome,
Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome,
Proteus-like syndrome, and autism spectrum disorder with
macrocephaly [27, 28]. Cowden syndrome, also known as
multiple hamartoma syndrome, is an autosomal dominant
disorder with high risk of breast, thyroid, and endometrium
cancer. The incidence of Cowden syndrome remains unclear
due to underdiagnosis from variable penetration and subtle
clinical ﬁndings [29]. Cowden syndrome is characterized by
the development of intestinal hamartomas, facial trichilem-
momas and mucocutaneous papillomatosis [29, 30], and is
rarely identiﬁed before adulthood [28]. PTEN mutations in
exon 5, coding for the active site and ﬂanking amino acids,
is a common site for mutations in patients with Cowden
syndrome, and missense mutations are only found in this
active area [30]. However, germline PTEN mutation has
been detected in approximately 80% of Cowden syndrome
patients [27]. The lifetime risk for endometrial carcinoma
in Cowden syndrome is approximately 5–10%, compared
with a 2.5% lifetime risk of women in the general pop-
ulation [27, 28]. Cowden syndrome and Bannayan-Riley-
Ruvalcaba syndrome have overlapping phenotypic features.Obstetrics and Gynecology International 9
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Figure 4:Carcinosarcomaiscomposedoftwomalignantcomponents,carcinomatousandsarcomatous.Theepithelialcomponentisusually
high grade carcinoma for example, serous/clear cell type. The mesenchymal part comprises either homologous (a), ×100 or heterologous
element for example, cartilage or bone. Chondrosarcomatous element (∗)i sp r e s e n ti n( b ) ,×100.
Bannayan-Riley-Ruvalcaba syndrome is a congenital, auto-
somal dominant condition manifested by macrocephaly,
hamartomatous intestinal polyposis, lipomas, developmen-
tal delay or autism or both, and pigmented penile mac-
ules [29, 31]. Unlike Cowden syndrome, Bannayan-Riley-
Ruvalcaba syndrome tends to be diagnosed at early life [28].
Approximately 60% of Bannayan-Riley-Ruvalcabasyndrome
patients have an identiﬁable germline mutation in PTEN
gene [27]. This syndrome also has the same increased risk
of cancer as Cowden syndrome [29].
5.Carcinosarcoma
Carcinosarcomas (formerly known as malignant mixed
mesodermal or mullerian tumors) are highly aggressive,
biphasic neoplasms composed of carcinomatous and sar-
comatous components (Figure 4). Carcinosarcomas account
for 1-2% of all malignancies of uterine corpus [1]a n d
usually present in postmenopausal women. Uterine bleeding
isthemostfrequentpresentingsymptom.Thesetumorshave
traditionally been regarded as a subtype of uterine sarcomas
or as a mixture of true carcinoma and sarcoma, but they are
now regarded as metaplastic carcinomas or carcinomas with
sarcomatous metaplasia [1, 18, 32–34]. Carcinosarcomas can
be classiﬁed as type II endometrial carcinomas and their
epithelialcomponentcanresemblehighgradeendometrioid,
serous or clear cell carcinoma [35]. Etiologically, a few cases
may be secondary to prior pelvic irradiation. In addition,
an association between long term tamoxifen therapy and
development of uterine carcinosarcoma has been suggested
[32].
Schipf et al. [36] analyzed a series of 30 paraﬃn-
embedded carcinosarcomas, including 24 ovarian and 6
uterine, using ﬂuorescence in situ hybridization (FISH)
and CGH. Many carcinosarcomas contained aberrations on
chromosome 8 and 20 detected by FISH. FISH showed C-
MYC (8q24.12) and ZNF217 (20q13.2) ampliﬁcation in 78%
and 87%, respectively. The results demonstrate a uniform
pattern of chromosomal gains and losses in CGH analysis.
Gains or ampliﬁcations of 8q are the most common genetic
aberration in carcinosarcomas [35]. One of the genes located
within 8q is C-MYC ( 8 q 2 4 )f o u n dt ob ea m p l i ﬁ e di n1 8o f
23 uterine and ovarian carcinosarcomas through FISH and
overexpression in 9 of 9 uterine carcinosarcomas through
immunostaining. C-MYC ampliﬁcation is often present
in carcinomas but was also present in 6 of 12 uterine
leiomyomas and 11 of 23 uterine leiomyosarcomas [35].
LOH was seen in 5 of 6 uterine carcinosarcomas, and
identical alleles were lost in the epithelial and mesenchymal
components. p53 mutations and LOH for TP53 occur
frequently in both carcinosarcoma components which are
associated with frequent protein overexpression. Sherman et
al. [18] reported immunoreactivity of p53 in 7 (70%) of 10
carcinosarcomas and noted that the similar staining pattern
presented in both carinomatous and sarcomatous areas. In
about 20% of carcinosarcomas, MSI-high was described
with an 83% concordance between the carcinomatous and
sarcomatous components [1]. One study found identical
mutations of p53 and KRAS in the two components [33].
Fujii et al. [37] analyzed allelic status with polymorphous
microsatellite markers on 172 carcinomatous/sarcomatous
foci after microdissection of 17 carcinosarcomas. A close
relationship between the carcinomatous and the sarcoma-
tous component was found. No diﬀerence was seen in
CGH patterns of carcinosarcomas [36]. Moreover, there is
evidence that in most carcinosarcomas, the carcinomatous
and the sarcomatous components are genetically the same,
as shown for 21 of 25 carcinosarcomas (84%) using the
human androgen receptor (HUMARA) for detection of X-
chromosome inactivation. These results support a mon-
oclonal origin of uterine carcinosarcomas and one can
hypothesizethateitherthesarcomatouscomponentdevelops
from the carcinomatous component (conversion theory) or
both are derived from a stem cell that undergoes divergent
diﬀerentiation (combination theory) [33]. In the process
of epithelial-mesenchymal transition, cells of epithelial ori-
gin lose epithelial characteristics and polarity acquiring a
mesenchymal phenotype with increased migratory behavior.10 Obstetrics and Gynecology International
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Figure 5: Endometrial stromal sarcoma, low grade is circumscribed from the surrounding myometrium (a), ×40; and higher magniﬁcation
of endometrial stromal sarcoma shows round uniform tumor cells resembling the stroma of proliferative endometrium with low mitotic
rate (b), ×200.
By molecular mechanisms, down-regulation of epithelial
markersandup-regulationofmesenchymalmarkersresultin
acquisitionofaﬁbroblast-likemorphologywithcytoskeleton
reorganization and increase in motility, invasiveness, and
metastatic capacity. A hallmark of epithelial-mesenchymal
transition is loss of E-cadherin expression. A number of
speciﬁc transcription factors, including Snail, Slug, SIP-1,
andTwist,contributetoinductionofepithelialmesenchymal
transition, acting as transcriptional repressors of the E-
cadherin gene. The oncogenic serine/threonine kinase AKT
also promotes the process, modulating several signaling and
transcriptionalnetworkslinkingWnt/β-catenin,NF-κB/p65,
and Rb [38]. However, some investigators also found that a
subset of carcinosarcoma was biclonal tumor, consisting of
independent unrelated carcinomas and sarcomas, according
to X chromosome inactivation and clinicopathological crite-
ria[35].Intwocollisionreportedtumors,thecarcinomatous
and sarcomatous components were histologically separate,
with no intermingling, and there was a nodal metastasis
that consisted purely of the sarcomatous element from one
of these tumors [33]. One study examined 26 carcinosarco-
mas and found adenosarcoma-like components in 4 cases,
suggesting that many of the true collision lesions may arise
from malignant transformation of either benign epithelium
within an adenosarcoma or adjacent benign endometrium
[35]. The prognosis of the collision tumor depends on
the most aggressive component, and may be better than
for a carcinosarcoma of similar stage [33]. Overall, the
carcinomatous component has been shown to have a more
aggressive behavior and be a better predictor of clinical
outcome in carcinosarcomas [35].
6. Endometrial Stromal Sarcoma and
Undifferentiated Endometrial Sarcoma
Endometrial stromal sarcoma and undiﬀerentiated endome-
trial sarcoma are in the same neoplastic spectrum. Diag-
nosis of endometrial stromal tumors has been based on
histologic criteria. Low grade endometrial stromal sar-
coma is composed of uniform, oval to spindle-shape cells
of endometrial stromal-type with numerous small arteri-
oles that resemble the spiral arterioles of late secretory
endometrium. Mitotic rate is not a consideration in the
distinction between low and high grade stromal sarcoma.
In addition, characteristic tongue-like growth of the stromal
cells into the myometrium and/or myometrial vasculature
is noted [39, 40]( Figure 5). Endometrial stromal sarcoma
usually occurs in middle aged women [41], and most
present with uterine bleeding. Undiﬀerentiated endome-
trial sarcoma, on the other hand, is deﬁned as a high-
grade neoplasm that lacks speciﬁc diﬀerentiation and bears
no histological resemblance to endometrial stroma. Also,
undiﬀerentiated endometrial sarcomas have marked nuclear
pleomorphism with high mitotic rate and display destructive
myometrial invasion [40, 42]. Undiﬀerentiated endometrial
sarcomas should be diagnosed only after extensive sam-
pling to exclude smooth or skeletal muscle diﬀerentiation,
to exclude high grade leiomyosarcoma or rhabdomyosar-
coma. Carcinosarcoma or adenosarcoma with sarcomatous
overgrowth should also be excluded before making the
diagnosis of undiﬀerentiated endometrial sarcomas [39,
40].
In endometrial stromal sarcomas, the tumor cells are
typically immunoreactive for estrogen and progesterone
receptors, CD10, vimentin, and sometimes focally with
actin, while they are generally negative for desmin, and
h-caldesmon. Expression of androgen receptor is observed
in 41% of examined sarcoma cases [41]. Approximately
70% of low grade endometrial stromal sarcomas also
expresses epidermal growth factor receptor (EGFR; HER1).
Undiﬀerentiated endometrial sarcomas are estrogen and
progesterone receptor negative, but a high proportion is
EGFR positive. Endometrial stromal sarocmas are typically
diploid with a low S-phase fraction whereas S-phase fraction
exceeds 10% in undiﬀerentiated endometrial sarcomas [41].
No c-kit (CD117) expression has been demonstrated in
endometrial stromalsarcomas[43]. Liegl et al. [43] found 22
of 37 endometrial stromal sarcomas showed platelet-derive
growth factor (PDGF)-α (CD140α)a n d8o f3 7e n d o m e t r i a l
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In contrast to epithelial endometrial carcinoma, en-
dometrial stromal tumors are characterized by distinct
cytogenetic abnormalities, particularly translocations lead-
ing to gene fusion. Cytogenetic studies reported to-date
are primarily for low grade endometrial stromal sarcomas,
mostly showing rearrangement of chromosomes 6, 7, and 17
[44, 45]. Loss of chromosome arm 7p (55.6% of the cases) is
the most frequent aberration and may play a role in tumor
development and progression [41]. Reverse transcription
polymerase chain reaction (RT-PCR) and FISH studies on
large series showed the presence of t(7;17)(p15;q21), leading
to the fusion of two zinc ﬁnger genes, JAZF1 (juxtaposed
with another zinc ﬁnger gene 1) and JJAZ1 (joined to JAZF1;
also named SUZ12, suppressor of zeste-12 protein). JAZF1
is expressed in normal endometrial stroma, but the speciﬁc
functions of the JAZF1 and the JJAZ1 g e n e sa sw e l la st h e
JAZF1/JJAZ1 fusion gene are still unknown [1, 42]. Based
on the evidence of loss of expression for normal versions
of JAZF1 in multiple tumors suggests a possible role of
this gene as a tumor suppressor [42]. This gene fusion is
a distinctive molecular genetic alteration for endometrial
stromal sarcoma and benign endometrial stromal nodules
[1, 41]. The JAZF1/JJAZ1 fusion gene is frequently present in
classicalendometrialstromalsarcomasandlessoftenincases
with variant histology [46]. However, of seven high-grade
endometrial stromal sarcomas/undiﬀerentiated endometrial
sarcomas studied, only three cases showed evidence of the
fusion [42]. In contrast, many studies reported the fusion
gene to be absent in undiﬀerentiated endometrial sarcomas
[41]. The fusion gene is not present in normal endometrial
stroma [41]. The presence of the JAZF1/JJAZ1 fusion gene
within the spectrum of endometrial stromal tumors from
benign to malignant raises possibility that the endometrial
stromal nodule may transform into malignant endometrial
stromal sarcoma [41, 47]. The frequencies of this gene
fusion in low grade endometrial stromal sarcoma have been
reported in many studies showing a wide range of positivity,
23–80% [44, 46, 48, 49]. The studies with RT-PCR only can
give false-positive results due to PCR contamination. FISH
may be useful as a complementary technique to exclude the
possibility of false positive contamination of cases by RT-
PCR [44]. Although the JAZF1/JJAZ1 fusion gene seems to
be the major molecular alterations in endometrial stromal
sarcomas, there is some evidence for alternative pathways in
the development of endometrial stromal sarcomas. A major
subgroup of endometrial stromal sarcomas has been found
to have translocations involving short arm of chromosome
6, particularly band 6p21 [41, 44, 45]. Micci et al. [50]
showed that the PHF1 (PHD ﬁnger protein 1) gene in
6p21 was recombined with two diﬀerent partners, (i)
with JAZF1 gene showing a 6p;7p rearrangement, which
results in the formation of a JAZF1/PHF1 fusion gene and
(ii) with EPC1 (enhancer of polycomb) gene in 10p11
that had a 6;10;10 translocation. Panagopoulos et al. [45]
introduced that a low-grade endometrial stromal sarcoma
cell line carrying a der(7)t(6;7)(p21;p22) also harbors a
JAZF1/PHF1fusion.Botht(7;17)andt(6;7)comprise62%of
the reported endometrial stromal sarcomas [44]. Addition-
ally, few endometrial stromal sarcoma cases were reported
with a t(X;17)(p11.2;q23) and a t(10;17)(q22;p13) [51–53].
Although JAZF1/JJAZ1 fusion may not be universally present
inalllowgradeendometrialstromalsarcoma,thisaberration
may still be diagnostically useful [44]. The JAZF1/JJAZ1
fusion has been identiﬁed in areas of smooth muscle dif-
ferentiation in endometrial stromal neoplasms (50% of the
cases). This ﬁnding supports that the endometrial stromal
and smooth muscle components of these tumors have the
same origin, either from a common precursor cell with
pluripotential diﬀerentiation or from endometrial stromal
cells that have undergone smooth muscle metaplasia [44,
54]. Halbwedl et al. [55] described 9 cases of low grade
endometrial stromal sarcoma and 3 cases of undiﬀerentiated
endometrial sarcoma in aCGH study revealing a variety
of gains and losses that apparently did not correlate with
morphology. There is no accumulation of aberrations in
undiﬀerentiated endometrial sarcoma compared to endome-
trial stromal sarcoma, indicating these two types of uterine
sarcomas are probably not related to each other.
LOH and MSI have been evaluated in both low grade
endometrial stromal sarcomas (20 cases) and undiﬀeren-
tiated endometrial sarcomas (3 cases). LOH with at least
one polymorphic DNA marker was identiﬁed in all 3
cases (100%) of undiﬀerentiated endometrial sarcomas, 10
(50%)low-gradeendometrial stromalsarcomasand2(50%)
benign endometrial stromal nodules. Moreover, concurrent
and independent LOH were noted in adjacent normal
appearing myometrium or endometrium, either close to
or at a distance from the tumors [41]. LOH was mostly
identiﬁed at PTEN, a tumor suppressor gene located on
chromosome 10q [56]. No tumor was associated with MSI
[41, 55]. Loss of functions of certain tumor suppressor genes
such as PTEN in surrounding nontumor uterine tissues
could inﬂuence and facilitate tumor proliferation, cellular
spread, and invasion by malignant endometrial stromal cells
[41]. However, one should keep in mind the false positive
scoring of LOH in normal tissues may occur both from the
imperfect methodology and from contamination by tumor
samples/cells. The use of repeated experiments and several
polymorphic markers has been advised to overcome these
methodology problems [56]. Other frequently altered loci
by LOH were at 14q32 (D14S267) and 3p (D3S1300). The
former locus is frequently altered in uterine leiomyosarcoma
but, in addition, in a variety of epithelial neoplasms such
as ovarian, colorectal and esophageal carcinoma. Locus
D3S1300harborstheFHIT genewhichisfrequentlymutated
in cervical carcinoma of the uterus. LOH for TP53 and
p53 overexpression are rarely present in endometrial stromal
sarcomas (5% and 15%, resp.). The importance of p53
mutations for the development of undiﬀerentiated endome-
trial sarcomas is not evident, but p53 overexpression was
detected in three of four high-grade stromal sarcomas [1].
Furthermore, Kurihara et al. [49]h a v er e c e n t l yf o u n df r e -
quent nuclear accumulation of p53 and TP53 gene missense
mutations in undiﬀerentiated endometrial sarcoma with
nuclear pleomorphism, 3 (50%) of 6 cases. There is no
evidence of p53 aberration in 18 low grade endometrial
stromal sarcomas and 7 cases undiﬀerentiated endometrial
sarcoma with nuclear uniformity. p53 alteration may be12 Obstetrics and Gynecology International
Table 3: Typical immunoproﬁle of type I endometrioid carcinoma
and type II serous carcinoma.
Endometrioid
carcinoma
Serous
carcinoma
Estrogen and
progesterone receptors + −
PTEN − +
β-catenin + −
p53 − +
HER2/neu − +
+: positive result, −: negative result
one diﬀerent pathway that contributes the tumorigenesis of
undiﬀerentiated endometrial sarcoma. Expression of SFRP4
and β-catenin is also detected. SFRP4 acts in Wnt-signaling
pathway, which is a complex cascade of heterogeneous
molecules playing an important role in organ development,
via β-catenin. SFRP4 i se x p r e s s e di nn o r m a le n d o m e t r i a l
stromal cells but not in glandular epithelium. Compared
with normal endometrium, the expression of SFRP4 was
decreased in both low grade endometrial stromal sarcomas
and undiﬀerentiated endometrial sarcomas. Through its
involvement in the Wnt signaling pathway, SFRP4 may act as
atumorsuppressorbyregulatingthecytosolicβ-cateninpool
in the cell. Beta-catenin regulates in the opposite manner
to SFRP4, being particularly increased in undiﬀerentiated
sarcoma [57]. Dysregulation of these pathways allows β-
catenin to accumulate and translocate to the nucleus, where
it forms complexes with T-cell factor/lymphoid enhancing
factor (TCF/LEF) leading to uncontrolled cell growth and
carcinogenesis [57]. High level nuclear staining for β-catenin
was seen in 40% of endometrial stromal sarcomas and may
be used as a diagnostic tool [42].
7.DiagnosticUtilityBased on
the MolecularKnowledge
7.1. Endometrioid Carcinoma versus Serous/Clear Cell Car-
cinoma. At times, the histological type of endometrial
carcinoma is not clearly deﬁned, especially in poorly diﬀer-
entiated tumors, and knowledge of the dualistic model, with
the common molecular changes in each type, can help clarify
the diagnosis. If there is non-carcinomatous endometrium
present, the presence of hyperplasia is supportive evidence of
an endometrioid carcinoma, whereas atrophic endometrium
is supportive of non-endometrioid carcinoma.
Molecular studies on endometrium are not often per-
formed in most hospital surgical pathology laboratories
today; however, immunohistochemical studies can detect the
abnormalproteinproductsofthegenemutations.Therefore,
we can exploit our knowledge of the dualistic model and
their typical gene mutations and use the immunoproﬁle
as a diagnostic tool, in concert with the histomorphologic
features to specify the tumor type, particularly in diﬃcult
cases such as in the diﬀerentiation between high-grade
endometrioid carcinoma and serous carcinoma (Table 3).
7.2. Endometrial Stromal Sarcoma versus Undiﬀerentiated
Sarcoma. The distinct molecular alteration described in
the majority of endometrial stromal sarcomas is the
t(7;17)(p15;q21) leading to the formation of fusion gene
JAZF1/JJAZ1,w h i c hc a nb ed e t e c t e db yR T - P C Ro rF I S H
assays. Thus, in the problematic cases in which the diﬀer-
entiatial diagnosis is between endometrial stromal sarcoma
and undiﬀerentiated sarcoma, we look for the fusion gene to
make this distinction.
7.3. Uterine Smooth Muscle Neoplasm versus Endome-
trial Stromal Tumors. Uterine smooth muscle neoplasm is
deﬁned as a mesenchymal tumor composed of cells with
smooth muscle diﬀerentiation, particularly highly cellular
leiomyomas may have morphologically overlapped features
of endometrial stromal tumors. According to histologic
criteriafordiﬀerential,immunostainingsmayhelptocorrect
the ﬁnal diagnosis, particularly in diﬃcult cases. Neoplastic
endometrialstromalcellstypicallyexpressvimentin,muscle-
speciﬁc and smooth muscle actin and may be positive
for desmin. In addition, CD10, initially thought to be a
speciﬁc marker for endometrial stromal tumors, can be
demonstrated in uterine smooth muscle tumors, commonly
in highly cellular leiomyomas and leiomyosarcomas. Other
antibodies that give positive staining in smooth muscle
tumors useful in this diﬀerential diagnosis includes h-
caldesmon, histone deacetylase 8 (HDAC8), smooth muscle
myosin and oxytocin receptor [39]. However, none of
these markers can completely specify the smooth mus-
cle/endometrial stroma lineage of the tumor, a panel of the
antibodies should be used [39].
The molecular alterations in smooth muscle tumor are
complex, especially in leiomyosarcomas. The translocation
t(12;14)(q15;q23-24) has been noted in a high proportion
of leiomyomas [41, 58]. By CGH, leiomyosarcomas have
the most frequent losses including 10q, 11q, 13q, and 2p
while the most common gains are Xp, 1q, 5p, 8q, 12q, 17p
and 19p [41, 59, 60]. There are a variety of genetic changes
and mutations inclusive of TP53 and MDM2 expression
associated with progression of leiomyosarcomas [41]. LOH
of 10q is found in more than half of leiomyosarcomas [41].
Leiomyosarcomas exhibit a signiﬁcantly higher frequency of
allelic loss (52%) compared with benign leiomyomas (18%)
a n ds m o o t hm u s c l et u m o r so fu n c e r t a i nm a l i g n a n tp o t e n t i a l
(21%) [41].
8.TherapeuticConsiderations:
Molecular Targeted Therapy
Development of targeted anticancer drugs is the direct
result of knowledge of the molecular proﬁle of endometrial
neoplasms. Drug targets may focus on genes that aﬀect
apoptosis, signaltransduction,epigeneticmodiﬁcation, drug
resistance, protein folding and degradation, cell cycle pro-
gression, hormone receptor activity, and angiogenesis [4].
The drugs that comprise targeted therapy include small
molecular weight inhibitors, monoclonal antibodies, anti-
sense and gene therapy [61]. At this time, essentially onlyObstetrics and Gynecology International 13
endometrial carcinomas have been tested with targeted
therapy.Carcinosarcomasandendometrialstromalsarcomas
are relatively uncommon neoplasms, and there has little
experience with speciﬁc therapies for these tumors, though
there is deﬁnitely future potential.
8.1. mTOR Inhibitors. The phosphatidylinositol-3-kinase
(PI3K)-serine/threonine kinase (AKT)-mammalian target of
the rapamycin (mTOR) signaling pathway plays a central
role in the regulation of cell growth, proliferation, and
apoptosis. In in vitro studies, cells with PTEN inactivation in
endometrioid carcinoma are sensitive to mTOR inhibitors,
since the loss of PTEN leads to constitutive activation
of downstream components, which in turn up-regulates
mTOR activity [62]. Potential therapies targeting the mTOR
pathway include the mTOR inhibitors temsirolimus (CCI-
779),everolimus(RAD001),anddeforolimus(AP23573)[4].
In a phase II study of temsirolimus activity in patients with
advanced or recurrent endometrial cancer, 5 of 19 (26%)
evaluable patients had a partial response and 12 (63%) had
stable disease [62, 63]. In addition to mTOR inhibitors,
other agents targeting components of the mTOR-AKT-
PI3K-PTEN pathway have also been developed, including
enzastaurin (a PI3K inhibitor) and triciribine (an AKT
inhibitor) [4].
8.2.EGFRInhibitors/Anti-HER2/neu. Epidermalgrowthfac-
tor receptor (EGFR) family members (ERBB1 (EGFR
or HER1), ERBB2 (HER2/neu), ERBB3 (HER3), ERBB4
(HER4)) are tyrosine kinase receptors that are activated by
bindingtoepidermalgrowthfactor(EGF)-likegrowthfactor,
leading to downstream phosphorylation or dephosphoryla-
tion of signaling molecules that involved in cell cycle and
apoptosis [63]. Sixty to 80% of endometrial carcinomas
overexpress EGFR [4]. In addition, EGFR expression has
beendescribedinapproximately70%ofendometrialstromal
sarcomas [41]. EGFR overexpression has been reported
in high grade carcinomas with deep myometrial invasion,
positive peritoneal washings and poor survival [61, 63].
The anti-EGFR agents result in down regulation of the
MAPK and PI3K/AKT signaling pathways. However, the
anti-tumor activity has been described in a minority of the
patientstreated.AntagoniststoEGFRincludesmallmolecule
tyrosine kinase inhibitors (geﬁtinib, erlotinib, and lapatinib)
and the anti-EGFR monoclonal antibody cetuximab [62].
Experimental observation data have been shown that EGFR
inhibitors could be more eﬀective in endometrioid endome-
trial carcinoma than in uterine papillary serous carcinoma
[63]
As described above, HER2/neu gene overexpression
and ampliﬁcation have been found in up to 80% of
nonendometrioid endometrial carcinoma, and in 10–
30% of endometrioid endometrial carcinoma. The usage
of trastuzumab, a monoclonal antibody directed against
HER2/neu, has been tested in endometrial carcinomas. Vil-
lella’s group found 5 out of 19 (26%) patients with papillary
serous carcinoma showed HER2/neu overexpression. One
of 5 positive HER2/neu patients with advanced disease
treated with trastuzumab achieved a complete response
and a second patient’s disease stabilized [63]. However
in another study, Gynecologic Oncology Group (GOG)-
0181-B, investigated trastuzumab in advanced, recurrent, or
persistent endometrial cancer, and its preliminary results
showed minimal activity, even in cancers with high over-
expression of HER2/neu [4]. Several other monoclonal
antibodies targeting members of the ERBB/HER family,
including pertuzumab, cetuximab, and panitumumab, are
currently being investigated [4].
8.3. Antiangiogenics. Vascular endothelial growth factors
(VEGF) expression has been found in 56–100% of endome-
trial carcinomas [63] and has been correlated with high
histologic grade, deep myometrial invasion, angiolymphatic
invasion, nodal metastasis, and short disease-free survival
[63, 64]. VEGF, particularly VEGF-A, plays a key role in
angiogenesis and increased permeabilityof tumor-associated
blood vessels. Monoclonal antibodies targeting VEGF, beva-
cizumab and sorafenib, have been developed. Kamat and
coworkers [64] injected Ishikawa cell line into uterine horn
of nude mice in one group and Hec-1A cell lines in the
other group and treated the mice with docetaxel and/or
bevacizumab. The combination of both agents had a greater
eﬃcacy in tumor growth inhibition than a single agent.
Currently, GOG-229-E is being studied in a phase II trial
of single agent bevacizumab in patients with recurrent
endometrial carcinoma [64].
9. Conclusion
Knowledge of the molecular proﬁles of endometrial neo-
plasms assists in the diagnosis, prognosis, and treatment
of endometrial neoplasms. Endometrial carcinoma can
be broadly divided into two categories based on clinical
behaviorandmorphologicphenotype,withgoodcorrelation
to the molecular ﬁndings. Type I endometrial carcinoma
represents an estrogen-related tumor, which usually arises
in the setting of endometrial hyperplasia and have good
prognosis. They are associated with a number of well-
described genetic alterations including mutations of PTEN,
KRAS, β-catenin, PIK3CA, and inactivation of DNA mis-
match repair. Targets for molecular therapy in endometrial
carcinoma include agents that inhibit components of the
AKT-PI3K-PTEN pathway. Type II endometrial cancers are
not estrogen-related and have poor prognosis. Mutations of
p53 are present in approximately 90% of this tumor type.
Carcinosarcoma is considered to be a high-grade carcinoma
with sarcomatous diﬀerentiation and a high frequency
of C-MYC mutations and LOH of p53.T h em a j o r i t yo f
endometrial stromal nodules and stromal sarcomas seem to
originate from the abnormal JAZF1/JJAZ1 gene fusion. The
molecular biology of undiﬀerentiated endometrial sarcomas
is still not clearly delineated. In the near future; additional
molecular studies should further elucidate the unclear
pathogenesis and provide new targets for diagnosis and
treatment.14 Obstetrics and Gynecology International
References
[1] S. F. Lax, “Molecular genetic changes in epithelial, stromal and
mixed neoplasms of the endometrium,” Pathology, vol. 39, no.
1, pp. 46–54, 2007.
[ 2 ]S .G .S i l v e r b e r g ,R .J .K u r m a n ,F .N o g a l e s ,G .M u t t e r ,R .
A. Kubik-Huch, and F. A. Tavassoli, “Epithelial tumors and
related lesions,” in Pathology and Genetics of Tumors of the
Breast and Female Organs,P .D e v i l e ea n dF .A .T a v a s s o l i ,E d s . ,
IARC Press, Lyon, France, 2003.
[3] M. J. Horner, L. A. G. Ries, M. Krapcho, et al., “SEER Cancer
Statistics Review 1975–2006,” 2009, http://seer.cancer.gov/csr/
1975 2006/.
[4] N. Bansal, V. Yendluri, and R. M. Wenham, “The molecular
biology of endometrial cancers and the implications for
pathogenesis, classiﬁcation, and targeted therapies,” Cancer
Control, vol. 16, no. 1, pp. 8–13, 2009.
[5] J. V. Bokhman, “Two pathogenetic types of endometrial
carcinoma,” Gynecologic Oncology, vol. 15, no. 1, pp. 10–17,
1983.
[6] A. Di Cristofano and L. H. Ellenson, “Endometrial carci-
noma,” Annual Review of Pathology, vol. 2, pp. 57–85, 2007.
[7] D. Llobet, J.Pallares, A.Yeramian, et al., “Molecular pathology
of endometrial carcinoma: practical aspects from the diagnos-
tic and therapeutic viewpoints,” Journal of Clinical Pathology,
vol. 62, no. 9, pp. 777–785, 2009.
[8] X. Matias-guiu, L. Catasus, E. Bussaglia, et al., “Molecu-
lar pathology of endometrial hyperplasia and carcinoma,”
Human Pathology, vol. 32, no. 6, pp. 569–577, 2001.
[9] J.Prat,A.Gallardo,M.Cuatrecasas,andL.Catas´ us,“Endome-
trial carcinoma: pathology and genetics,” Pathology, vol. 39,
no. 1, pp. 72–87, 2007.
[10] F.-S. Liu, “Molecular carcinogenesis of endometrial cancer,”
Taiwanese Journal of Obstetrics and Gynecology, vol. 46, no. 1,
pp. 26–32, 2007.
[11] S. F. Lax, “Molecular genetic pathways in various types of
endometrial carcinoma: from a phenotypical to a molecular-
based classiﬁcation,” Virchows Archiv, vol. 444, no. 3, pp. 213–
223, 2004.
[12] J. L. Hecht and G. L. Mutter, “Molecular and pathologic
aspects of endometrial carcinogenesis,” Journal of Clinical
Oncology, vol. 24, no. 29, pp. 4783–4791, 2006.
[13] A. Doll, M. Abal, M. Rigau, et al., “Novel molecular proﬁles of
endometrial cancer-new light through old windows,” Journal
ofSteroidBiochemistryandMolecularBiology,vol.108,no.3-5,
pp. 221–229, 2008.
[14] S. N. Westin, R. R. Broaddus, L. Deng, et al., “Molecular
clustering of endometrial carcinoma based on estrogen-
induced gene expression,” Cancer Biology & Therapy, vol. 8,
no. 22, pp. 2126–2135, 2009.
[15] L. Catasus, A. Gallardo, M. Cuatrecasas, and J. Prat, “Con-
comitant PI3K-AKT and p53 alterations in endometrial carci-
nomas areassociated withpoorprognosis,” Modern Pathology,
vol. 22, no. 4, pp. 522–529, 2009.
[ 1 6 ]Y .K a r a m u r z i na n dJ .K .L .R u t g e r s ,“ D N Am i s m a t c hr e p a i r
deﬁciency in endometrial carcinoma,” International Journal of
Gynecological Pathology, vol. 28, no. 3, pp. 239–255, 2009.
[17] H. Tashiro, M. S. Blazes, R. Wu, et al., “Mutations in PTEN are
frequent in endometrial carcinoma but rare in other common
gynecological malignancies,” Cancer Research, vol. 57, no. 18,
pp. 3935–3940, 1997.
[18] M. E. Sherman, M. E. Bur, and R. J. Kurman, “p53 in
endometrial cancer and its putative precursors: evidence for
diverse pathways of tumorigenesis,” Human Pathology, vol. 26,
no. 11, pp. 1268–1274, 1995.
[ 1 9 ] J .P a l l a r e s ,E .B u s s a g l i a ,J .L .M a r t ´ ınez-Guitarte, et al.,
“Immunohistochemical analysis of PTEN in endometrial
carcinoma: a tissue microarray study with a comparison of
four commercial antibodies in correlation with molecular
abnormalities,” Modern Pathology, vol. 18, no. 5, pp. 719–727,
2005.
[20] A. Velasco, E. Bussaglia, J. Pallares, et al., “PIK3CA gene
mutations in endometrial carcinoma. Correlation with PTEN
and K-RAS alterations,” Human Pathology, vol. 37, no. 11, pp.
1465–1472, 2006.
[21] A. Dutt, H. B. Salvesen, H. Greulich, W. R. Sellers, R.
Beroukhim, and M. Meyerson, “Somatic mutations are
present in all members of the AKT family in endometrial
carcinoma,”BritishJournalofCancer,vol.101,no.7,pp.1218–
1219, 2009.
[22] H. Tashiro, C. Isacson, R. Levine, R. J. Kurman, K. R. Cho,
and L. Hedrick, “p53 gene mutations are common in uterine
serous carcinoma and occur early in their pathogenesis,”
American Journal of Pathology, vol. 150, no. 1, pp. 177–185,
1997.
[ 2 3 ]R .A .A m b r o s ,M .E .S h e r m a n ,C .M .Z a h n ,P .B i t t e r m a n ,a n d
R. J. Kurman, “Endometrial intraepithelial carcinoma: a dis-
tinctive lesion speciﬁcally associated with tumors displaying
serous diﬀerentiation,” Human Pathology, vol. 26, no. 11, pp.
1260–1267, 1995.
[24] L. A. Meyer, R. R. Broaddus, and K. H. Lu, “Endometrial
cancer and lynch syndrome: clinical and pathologic consider-
ations,” Cancer Control, vol. 16, no. 1, pp. 14–22, 2009.
[25] K. Garg and R. A. Soslow, “Lynch syndrome (hereditary non-
polyposis colorectal cancer) and endometrial carcinoma,”
Journal of Clinical Pathology, vol. 62, no. 8, pp. 679–684, 2009.
[26] T. T. Nieminen, A. Gylling, W. M. Abdel-Rahman, et al.,
“Molecular analysis of endometrial tumorigenesis: impor-
tance of complex hyperplasia regardless of atypia,” Clinical
Cancer Research, vol. 15, no. 18, pp. 5772–5783, 2009.
[27] R. Pilarski, “Cowden syndrome: a critical review of the clinical
literature,” JournalofGeneticCounseling,v ol.18,no .1,p p .13–
27, 2009.
[28] J.A.HobertandC.Eng,“PTENhamartomatumorsyndrome:
an overview,” Genetics in Medicine, vol. 11, no. 10, pp. 687–
694, 2009.
[29] K. M. Schmeler, M. S. Daniels, A. C. Brandt, and K. H. Lu,
“Endometrial cancer in an adolescent: a possible manifesta-
tion of Cowden syndrome,” Obstetrics and Gynecology, vol.
114, no. 2, part 2, pp. 477–479, 2009.
[30] M. R. Nelen, W. C. G. Van Staveren, E. A. J. Peeters, et al.,
“Germline mutations in the PTEN/MMAC1 gene in patients
with Cowden disease,” Human Molecular Genetics, vol. 6, no.
8, pp. 1383–1387, 1997.
[31] N. E. Lynch, S. A. Lynch, J. McMenamin, and D. Webb,
“Bannayan-Riley-Ruvalcaba syndrome: a cause of extreme
macrocephaly and neurodevelopmental delay,” Archives of
Disease in Childhood, vol. 94, no. 7, pp. 553–554, 2009.
[32] W. G. McCluggage, U. Haller, R. J. Kurman, and R. A.
Kubik-Huch, “Mixed epithelial and mesenchymal tumors,” in
Pathology and Genetics of Tumors of the Breast and Female
Organs, P. Deville and F. A. Tavassoli, Eds., IARC Press, Lyon,
France, 2003.Obstetrics and Gynecology International 15
[33] W. G. McCluggage, “Malignant biphasic uterine tumours: car-
cinosarcomas or metaplastic carcinomas?” Journal of Clinical
Pathology, vol. 55, no. 5, pp. 321–325, 2002.
[34] W. G. McCluggage, “Uterine carcinosarcomas (malignant
mixed Mullerian tumors) are metaplastic carcinomas,” Inter-
national Journal of Gynecological Cancer,v o l .1 2 ,n o .6 ,p p .
687–690, 2002.
[35] L. E. Kernochan and R. L. Garcia, “Carcinosarcomas (malig-
nant mixed m¨ ullerian tumor) of the uterus: advances in
elucidation of biologic and clinical characteristics,” Journal of
the National Comprehensive Cancer Network,v o l .7 ,n o .5 ,p p .
550–557, 2009.
[36] A. Schipf, D. Mayr, T. Kirchner, and J. Diebold, “Molecular
genetic aberrations of ovarian and uterine carcinosarcomas—
a CGH and FISH study,” Virchows Archiv, vol. 452, no. 3, pp.
259–268, 2008.
[37] H. Fujii, M. Yoshida, Z. X. Gong, et al., “Frequent genetic
heterogeneity in the clonal evolution of gynecological carci-
nosarcoma and its inﬂuence on phenotypic diversity,” Cancer
Research, vol. 60, no. 1, pp. 114–120, 2000.
[38] M. Saegusa, M. Hashimura, T. Kuwata, and I. Okayasu,
“Requirement of the Akt/β-catenin pathway for uterine
carcinosarcoma genesis, modulating E-cadherin expression
through the transactivation of slug,” American Journal of
Pathology, vol. 174, no. 6, pp. 2107–2115, 2009.
[39] P. Baker and E. Oliva, “Endometrial stromal tumours of the
uterus: a practical approach using conventional morphology
andancillarytechniques,”JournalofClinicalPathology,vol.60,
no. 3, pp. 235–243, 2007.
[40] M. R. Hendrickson, F. A. Tavassoli, and R. L. Kempson,
“Mesenchymal tumors and related lesion,” in Pathology and
Genetics of Tumors of the Breast and Female Organs,P .D e v i l e e
and F. A. Tavassoli, Eds., IARC Press, Lyon, France, 2003.
[41] F. Moinfar, M. Azodi, and F. A. Tavassoli, “Uterine sarcomas,”
Pathology, vol. 39, no. 1, pp. 55–71, 2007.
[42] A. A. Sandberg, “The cytogenetics and molecular biology
of endometrial stromal sarcoma,” Cytogenetic and Genome
Research, vol. 118, no. 2–4, pp. 182–189, 2007.
[43] B. Liegl, O. Reich, F. F. Nogales, and S. Regauer, “PDGF-α
and PDGF-β are expressed in endometrial stromal sarcoma:
a potential therapeutic target for tyrosine kinase inhibitors?”
Histopathology, vol. 49, no. 5, pp. 545–546, 2006.
[44] M. R. Nucci, D. Harburger, J. Koontz, P. D. Cin, and J. Sklar,
“Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-
PCR and ﬂuorescence in situ hybridization in endometrial
stromal neoplasms,” American Journal of Surgical Pathology,
vol. 31, no. 1, pp. 65–70, 2007.
[45] I. Panagopoulos, F. Mertens, and C. A. Griﬃn, “An endome-
trial stromal sarcoma cell line with the JAZF1/PHF1 chimera,”
Cancer Genetics and Cytogenetics, vol. 185, no. 2, pp. 74–77,
2008.
[46] H.-Y. Huang, M. Ladanyi, and R. A. Soslow, “Molecular
detection of JAZF1-JJAZ1 gene fusion in endometrial stromal
neoplasms with classic and variant histology: evidence for
genetic heterogeneity,” American Journal of Surgical Pathology,
vol. 28, no. 2, pp. 224–232, 2004.
[47] F. Moinfar, M.-L. Kremser, Y. G. Man, K. Zatloukal, F. A.
Tavassoli, and H. Denk, “Allelic imbalances in endometrial
stromal neoplasms: frequent genetic alterations in the non-
tumorous normal-appearing endometrial and myometrial
tissues,” Gynecologic Oncology, vol. 95, no. 3, pp. 662–671,
2004.
[ 4 8 ]A .H r z e n j a k ,F .M o i n f a r ,F .A .T a v a s s o l i ,e ta l . ,“ J A Z F 1 / J J A Z 1
gene fusion in endometrial stromal sarcomas. Molecular
analysis by reverse transcriptase-polymerase chain reaction
optimized for paraﬃn-embedded tissue,” Journal of Molecular
Diagnostics, vol. 7, no. 3, pp. 388–395, 2005.
[49] S. Kurihara, Y. Oda, Y. Ohishi, et al., “Endometrial stromal
sarcomas and related high-grade sarcomas: immunohisto-
chemical and molecular genetic study of 31 cases,” American
Journal of Surgical Pathology, vol. 32, no. 8, pp. 1228–1238,
2008.
[50] F. Micci, I. Panagopoulos, B. Bjerkehagen, and S. Heim,
“Consistent rearrangement of chromosomal band 6p21 with
generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in
endometrial stromal sarcoma,” Cancer Research, vol. 66, no. 1,
pp. 107–112, 2006.
[51] F. Amant, P. Moerman, I. Cadron, A. Hagemeijer, I. Vergote,
and M. Debiec-Rychter, “Endometrial stromal sarcoma with a
sole t(X;17) chromosome change: report of a case and review
of the literature,” Gynecologic Oncology, vol. 88, no. 3, pp. 459–
462, 2003.
[52] K. Leunen, F. Amant, M. Debiec-Rychter, et al., “Endometrial
stromal sarcoma presenting as postpartum haemorrhage:
report of a case with a sole t(10;17)(q22;p13) translocation,”
Gynecologic Oncology, vol. 91, no. 1, pp. 265–271, 2003.
[53] S. Regauer, W. Emberger, O. Reich, and R. Pfragner, “Cytoge-
netic analyses of two new cases of endometrial stromal sarco-
ma—non-random reciprocal translocation t(10;17)(q22;p13)
correlates with ﬁbrous ESS,” Histopathology, vol. 52, no. 6, pp.
780–783, 2008.
[54] E. Oliva, L. De Leval, R. A. Soslow, and C. Herens, “High
frequency of JAZF1-JJAZ1 gene fusion in endometrial stromal
tumors with smooth muscle diﬀerentiation by interphase
FISH detection,” American Journal of Surgical Pathology, vol.
31, no. 8, pp. 1277–1284, 2007.
[55] I. Halbwedl, R. Ullmann, M.-L. Kremser, et al., “Chromo-
somal alterations in low-grade endometrial stromal sarcoma
and undiﬀerentiated endometrial sarcoma as detected by
comparative genomic hybridization,” Gynecologic Oncology,
vol. 97, no. 2, pp. 582–587, 2005.
[56] F. Micci and S. Heim, “Pathogenetic mechanisms in endome-
trial stromal sarcoma,” Cytogenetic and Genome Research, vol.
118, no. 2–4, pp. 190–195, 2007.
[57] A. Hrzenjak, M. Tippl, M.-L. Kremser, et al., “Inverse
correlation of secreted frizzled-related protein 4 and β-
catenin expression in endometrial stromal sarcomas,” Journal
of Pathology, vol. 204, no. 1, pp. 19–27, 2004.
[58] J. C. Hodge, B. J. Quade, M. A. Rubin, E. A. Stewart, P. D. Cin,
and C. C. Morton, “Molecular and cytogenetic characteriza-
tion of plexiform leiomyomata provide further evidence for
genetic heterogeneity underlying uterine ﬁbroids,” American
Journal of Pathology, vol. 172, no. 5, pp. 1403–1410, 2008.
[59] B. Levy, T. Mukherjee, and K. Hirschhorn, “Molecular cyto-
genetic analysis of uterine leiomyoma and leiomyosarcoma
by comparative genomic hybridization,” Cancer Genetics and
Cytogenetics, vol. 121, no. 1, pp. 1–8, 2000.
[60] J. Yang, X. Du, K. Chen, et al., “Genetic aberrations in soft
tissue leiomyosarcoma,” Cancer Letters, vol. 275, no. 1, pp. 1–
8, 2009.
[61] A. N. Y. Cheung, “Molecular targets in gynaecological can-
cers,” Pathology, vol. 39, no. 1, pp. 26–45, 2007.
[62] S. M. Temkin and G. Fleming, “Current treatment of
metastatic endometrial cancer,” Cancer Control,v o l .1 6 ,n o .1 ,
pp. 38–45, 2009.16 Obstetrics and Gynecology International
[63] A. Gadducci, R. Tana, S. Cosio, A. Fanucchi, and A. R. Genaz-
zani, “Molecular target therapies in endometrial cancer: from
the basic research to the clinic,” Gynecological Endocrinology,
vol. 24, no. 5, pp. 239–249, 2008.
[64] A. A. Kamat, W. M. Merritt, D. Coﬀey, et al., “Clinical and
biological signiﬁcance of vascular endothelial growth factor in
endometrial cancer,” Clinical Cancer Research, vol. 13, no. 24,
pp. 7487–7495, 2007.